Phaseline

Companies › Thirty Respiratory

Thirty Respiratory: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Respiratory, Infectious disease; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RESP30TB
Nitric oxide agent
–Phase 2Pulmonary TuberculosesNov 2026
RESP302
Nitric oxide agent for inhalation
–Phase 1Non-Cystic Fibrosis BronchiectasisFeb 2028
RESP303
Nitric oxide agent for inhalation
–Phase 1Non-Cystic Fibrosis BronchiectasisFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07073638RESP30TBPhase 2Pulmonary TuberculosesInfectious diseaseNov 2026
NCT06663176RESP302Phase 1Non-Cystic Fibrosis BronchiectasisRespiratoryFeb 2028
NCT06663176RESP303Phase 1Non-Cystic Fibrosis BronchiectasisRespiratoryFeb 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Mundipharma Research Vicore Pharma SpliSense GEn1E Lifesciences Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.